On July 2, WuXi Biologics rose 3.47% in regular trading, trading at 35.84 HKD/share, with turnover of 531 million HKD.

On the news front, the company has maintained an aggressive buyback pace. On June 30, it spent approximately 99.83 million HKD to repurchase 2.89 million shares. Since May 26, cumulative repurchases have exceeded 37.1 million shares totaling approximately 1.172 billion HKD, signaling management confidence in the company's intrinsic value. Additionally, three factories at the company's Wuxi production base passed Brazil's ANVISA GMP certification with zero findings, further validating its global commercial manufacturing capabilities.

Within the Life Sciences Tools and Services sector, multiple stocks posted gains. Among individual stocks, GenScript Bio up 4.66%, WuXi XDC up 3.33%, Insilico up 2.12%, XtalPi up 1.96%, demonstrating notable sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)